HighTide Therapeutics (HKSE:02511) Equity-to-Asset : 0.88 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. HighTide Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$768.68 Mil. HighTide Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was HK$869.59 Mil.

The historical rank and industry rank for HighTide Therapeutics's Equity-to-Asset or its related term are showing as below:

HKSE:02511' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.55 Med: -0.35 Max: 0.88
Current: 0.88

During the past 3 years, the highest Equity to Asset Ratio of HighTide Therapeutics was 0.88. The lowest was -0.55. And the median was -0.35.

HKSE:02511's Equity-to-Asset is ranked better than
81.18% of 1562 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02511: 0.88

HighTide Therapeutics Equity-to-Asset Historical Data

The historical data trend for HighTide Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Equity-to-Asset Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Equity-to-Asset

-0.35

-0.55

0.88

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	-0.35	-	-0.55	-1.36	0.88

Competitive Comparison of HighTide Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, HighTide Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's Equity-to-Asset falls into.

HighTide Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

HighTide Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	768.679	/	869.594
	=

HighTide Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	768.679	/	869.594
	=

HighTide Therapeutics (HKSE:02511) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

HighTide Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines